share_log

Pono Capital Corp Combination Partner Benuvia Receives Approval From DEA To Manufacture Psychedelic Active Pharmaceutical Ingredients including Psilocybin, MDMA And DMT

Pono Capital Corp Combination Partner Benuvia Receives Approval From DEA To Manufacture Psychedelic Active Pharmaceutical Ingredients including Psilocybin, MDMA And DMT

Pono Capital Corp 合并合伙人 Benuvia 获得美国药物管理局批准生产迷幻活性药物成分,包括 psilocybin、MDMA 和 DMT
Benzinga Real-time News ·  2022/05/16 07:51
With this approval, Benuvia has begun focusing on four primary psychedelic ingredients: Psilocybin, N,N-Dimethyl-5-Methoxy-Tryptamine (5-MeO DMT), Dimethyltryptamine (DMT), and 3,4-Methylenedioxymethamphetamine, or MDMA Benuvia will manufacture psychedelic APIs in its 83,000 square foot manufacturing facility that is permitted by the US DEA for Schedule I to III Controlled Substances, and is FDA registered and a cGMP facility Benuvia is positioning itself to become a leading global supplier of psychedelic active pharmaceutical ingredients (APIs), complementing its established portfolio of cannabinoid APIs
获得批准后,Benuvia开始专注于四种主要的迷幻成分:裸盖菇素、N,N-二甲基-5-甲氧基色胺(5-MeO DMT)、二甲基色胺(DMT)和3,4-亚甲基二氧基甲基苯丙胺,或MDMA Benuvia将在其83,000平方英尺的制造工厂生产迷幻原料药,该工厂是美国DEA允许的附表I至III受控物质,并已在FDA注册,是一家cGMP工厂 Benuvia正在将自己定位为迷幻活性药物成分(API)的全球领先供应商,以补充其已建立的大麻类API产品组合
ROUND ROCK, Texas, May 16, 2022 /PRNewswire/ -- Benuvia, Inc., a drug developer and manufacturer of APIs focused on cannabinoids, with...
亚洲网得克萨斯州朗洛克2022年5月...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发